NASDAQ:CGEN - Compugen Stock Price, Forecast & News

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen Ltd. (NASDAQ:CGEN) announced its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.01. View Compugen's Earnings History.

Compugen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Compugen.

1 Wall Street analysts have issued 12-month target prices for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Compugen's stock price to reach $9.00 in the next year. This suggests a possible upside of 67.3% from the stock's current price. View Analyst Price Targets for Compugen.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.

News stories about CGEN stock have been trending very positive this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Compugen earned a media sentiment score of 3.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Compugen.

Some companies that are related to Compugen include Krystal Biotech (KRYS), Fate Therapeutics (FATE), Precision BioSciences (DTIL), SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Rubius Therapeutics (RUBY), BAVARIAN NORDIC/S (BVNRY), Vericel (VCEL), Twist Bioscience (TWST), MeiraGTx (MGTX), Cortexyme (CRTX), Atara Biotherapeutics (ATRA), Adverum Biotechnologies (ADVM) and DBV TECHNOLOGIE/S (DBVT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), Sarepta Therapeutics (SRPT), Pluristem Therapeutics (PSTI), Catalyst Pharmaceuticals (CPRX), Sorrento Therapeutics (SRNE), Protalix Biotherapeutics (PLX), Novavax (NVAX), REDHILL BIOPHAR/S (RDHL) and Amarin (AMRN).

Compugen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (15.26%), Taylor Frigon Capital Management LLC (1.46%), Rothschild Investment Corp IL (0.65%), Defender Capital LLC. (0.58%), Phoenix Holdings Ltd. (0.11%) and Benjamin F. Edwards & Company Inc. (0.07%).

CGEN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Benjamin F. Edwards & Company Inc., Rothschild Investment Corp IL, Taylor Frigon Capital Management LLC and Defender Capital LLC..

CGEN stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Phoenix Holdings Ltd., State Street Corp and Janney Montgomery Scott LLC.

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CGEN stock can currently be purchased for approximately $5.38.

Compugen has a market capitalization of $275.96 million and generates $17.80 million in revenue each year. The biotechnology company earns $-22,600,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Compugen employs 89 workers across the globe.View Additional Information About Compugen.

The official website for Compugen is http://www.cgen.com/.

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]